Mayo Clinic in Florida

Running trials

• Not yet recruiting

  Self-Collection for Cervical Cancer Screening and HPV Vaccination for Cancer Prevention Among Women in Emergency Care in Northeast Florida

  NCT06607874· Mayo Clinic· Source

• Not yet recruiting

  Low Dose Aspirin to Lower Inflammation and Prevent Endometrial Cancer in Postmenopausal Women With Non-atrophic Endometrial Changes and Pain

  NCT07281547· Phase 4· Mayo Clinic· Source

• Not yet recruiting

  A Study of Single Ascending Doses of NI112 in Adults With Amyotrophic Lateral Sclerosis (ALS)

  NCT07906665· Phase 1· Sachi Bioworks Inc.· Source

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A Study of the Effect of a Nurse Navigator Program on High Risk Patients

  NCT05592847· Mayo Clinic· Source

• Recruiting

  Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension

  NCT06770023· Phase 1· Mayo Clinic· Source

• Not yet recruiting

  Perioperative Risk in Patients on Chronic Aspirin Undergoing Craniotomy

  NCT07086183· Mayo Clinic· Source

• Not yet recruiting

  Advanced Imaging-Guided Standard Versus Dose-Intensified Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma, SAGA 2.0 Trial

  NCT07935889· Phase 3· Mayo Clinic· Source

• Recruiting

  Liver Transplantation From Donors With HIV: Impact on Opportunistic Infections, Cancer, and Long-Term Outcomes (Expanding HOPE Liver)

  NCT07665372· Johns Hopkins University· Source

• Not yet recruiting

  Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors

  NCT07769047· Phase 4· Mayo Clinic· Source

• Recruiting

  Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma

  NCT07708961· Phase 2· Mayo Clinic· Source

• Recruiting

  Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  NCT07805954· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Enrolling by invitation

  Dietary Sugar Absorptive Phenotype for Prediction of Weight Loss Outcome

  NCT05408728· Mayo Clinic· Source

• Recruiting

  Health and Wellness Coaching to Improve Adherence to Healthy Habits and Treatment Plans in Papillary and Follicular Thyroid Cancer Survivors

  NCT07545837· Mayo Clinic· Source

• Recruiting

  A Phase 1 Study of the Safety and Tolerability of CTX-10726

  NCT07419841· Phase 1· Compass Therapeutics· Source

• Recruiting

  Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

  NCT07621718· Phase 3· Revolution Medicines, Inc.· Source

• Recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

  NCT07589595· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men

  NCT07126548· Mayo Clinic· Source

• Recruiting

  Smart Symptom Tracking ALEX Application for Tracking and Monitoring Gastrointestinal Health, Smart Horizons Pilot Trial

  NCT07618273· Mayo Clinic· Source

• Recruiting

  The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

  NCT07218445· Phase 4· Mayo Clinic· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07450859· Phase 2· BicycleTx Limited· Source

• Recruiting

  A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  NCT07277413· Phase 1· IDEAYA Biosciences· Source

• Recruiting

  Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

  NCT06900595· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

  NCT07284758· Phase 2· C4 Therapeutics, Inc.· Source

• Recruiting

  Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

  NCT06997094· Phase 1· Mayo Clinic· Source

• Recruiting

  Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer

  NCT07073794· Phase 2· Mayo Clinic· Source

• Recruiting

  Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

  NCT07096778· Phase 2· CellCentric Ltd.· Source

• Recruiting

  A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

  NCT07321106· Phase 1· Cartography Biosciences· Source

• Recruiting

  A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  NCT07188558· Phase 3· Lyell Immunopharma, Inc.· Source

• Recruiting

  A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

  NCT07063745· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  Diagnosing Epilepsy To EffeCT Change Long-Term Follow-Up

  NCT07110454· Epiminder America, Inc.· Source

• Recruiting

  Diagnosing Epilepsy To EffeCT Change

  NCT07110337· Epiminder America, Inc.· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS

  NCT07287397· Phase 1/2· Vector Y Therapeutics· Source

• Recruiting

  The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas

  NCT07285044· Phase 2· Mayo Clinic· Source

• Recruiting

  A Long-term Follow-up Study in Patients Who Received BEAM-101

  NCT07373639· Beam Therapeutics Inc.· Source

• Recruiting

  BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma

  NCT07226856· Phase 2· Mayo Clinic· Source

• Recruiting

  Phase 1 Study of CLR 125 in Triple Negative Breast Cancer

  NCT07311993· Phase 1· Cellectar Biosciences, Inc.· Source

• Recruiting

  Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

  NCT07061964· Phase 2· National Cancer Institute (NCI)· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

  NCT06948448· Phase 2· Ono Pharmaceutical Co., Ltd.· Source

• Enrolling by invitation

  Minimally Invasive Molecular Approaches for the Detection of Barrett's Esophagus- High Grade Dysplasia and Esophageal Adenocarcinoma

  NCT07212491· Mayo Clinic· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System

  NCT07227532· Biosense Webster, Inc.· Source

• Recruiting

  A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

  NCT07008118· Phase 1· Incyte Corporation· Source

• Recruiting

  A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

  NCT07175038· Phase 2· AllRock Bio, Inc.· Source

• Active, not recruiting

  A Study Of Virtual Reality Vs Sham VR On Fibromyalgia

  NCT07202572· Mayo Clinic· Source

• Recruiting

  A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma, GHoST Trial

  NCT07074756· Mayo Clinic· Source

• Recruiting

  Feasibility and Effect of Wrapping Nerves With a Multi-Layer Perinatal Tissue Allograft During Prostatectomy

  NCT06940271· Mayo Clinic· Source

Showing 50 of 308.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer18 recruiting
• Childhood cancers13 recruiting
• Colorectal cancer13 recruiting
• Melanoma12 recruiting
• Multiple myeloma12 recruiting
• Pancreatic cancer12 recruiting
• Prostate cancer12 recruiting
• Bladder cancer11 recruiting
• Ovarian cancer10 recruiting
• Endometrial cancer9 recruiting
• Glioblastoma9 recruiting
• Liver and biliary tract cancer9 recruiting
• Head and neck cancer8 recruiting
• Kidney cancer8 recruiting
• Sarcoma8 recruiting
• ALS (motor neurone disease)7 recruiting
• Gastric and oesophageal cancer7 recruiting
• Metastatic breast cancer7 recruiting
• Epilepsy6 recruiting
• Myelodysplastic syndromes6 recruiting
• Neuroendocrine tumours6 recruiting
• Acute myeloid leukaemia5 recruiting
• Cervical cancer5 recruiting
• Obesity5 recruiting
• Triple-negative breast cancer5 recruiting
• Bronchiectasis4 recruiting
• High blood pressure4 recruiting
• Barrett's oesophagus3 recruiting
• Chronic kidney disease3 recruiting
• Dermatomyositis and polymyositis (myositis)3 recruiting
• Diffuse large B-cell lymphoma3 recruiting
• Follicular lymphoma3 recruiting
• Heart failure3 recruiting
• Myeloproliferative neoplasms3 recruiting
• Pulmonary arterial hypertension3 recruiting
• Alzheimer disease2 recruiting
• Brain aneurysm2 recruiting
• HIV2 recruiting
• Mantle cell lymphoma2 recruiting
• Mesothelioma2 recruiting
• Thyroid cancer2 recruiting
• Amyloidosis1 recruiting
• Aortic aneurysm1 recruiting
• Atrial fibrillation1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• COPD1 recruiting
• Crohn's disease1 recruiting
• Cystic fibrosis1 recruiting
• Frontotemporal dementia1 recruiting
• Hodgkin lymphoma1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• IgA nephropathy1 recruiting
• Insomnia1 recruiting
• Irritable bowel syndrome1 recruiting
• Lewy body dementia1 recruiting
• Meningioma1 recruiting
• Migraine1 recruiting
• Myasthenia gravis1 recruiting
• Osteoarthritis1 recruiting
• Parkinson disease1 recruiting
• Sickle cell disease1 recruiting
• Stroke1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting

Closed trials

• Completed

  Virtual Reality as a Tool to Lower Blood Pressure and Anxiety in Clinic Settings

  NCT06960057· Mayo Clinic· Source

• Terminated

  Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06790966· Phase 3· PDS Biotechnology Corp.· Source

• Completed

  Personalized Education and Genetic Counseling to Increase Genetic Testing in Patients With a Known Family History of Pancreatic Cancer

  NCT06744595· Mayo Clinic· Source

• Completed

  InBody Band 3 Fitness Tracker to Improve Health Outcomes and Quality of Life in Black Prostate Cancer Survivors

  NCT06703996· Mayo Clinic· Source

• Terminated

  Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial)

  NCT05554354· Phase 2· National Cancer Institute (NCI)· Source

• Completed

  Subjective Sleep Quality of Patients With Chronic Insomnia

  NCT06550388· Mayo Clinic· Source

• Completed

  Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP)

  NCT06470750· Mayo Clinic· Source

• Terminated

  Whole Food Plant-based Diet Effect on Obstructive Sleep Apnea

  NCT06395181· Mayo Clinic· Source

• Completed

  Anti-Diabetic Medications to Fight PD and LBD

  NCT06263673· Phase 4· Mayo Clinic· Source

• Completed

  Extracellular Vesicle Cargo in Obesity and Type 2 Diabetes

  NCT06401876· Mayo Clinic· Source

• Completed

  Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer

  NCT05730712· Phase 2· Mayo Clinic· Source

• Terminated

  CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

  NCT05689021· Phase 2· Mayo Clinic· Source

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Boehringer Ingelheim· Source

• Terminated

  Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)

  NCT05712694· Phase 3· Polaris Group· Source

• Completed

  iCCaRE Consortium Pilot Project 1: Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men

  NCT06535802· Mayo Clinic· Source

• Recruiting

  International Registry of Intra-arterial and Endosaccular Flow Diverters (IRF)

  NCT06174727· Montefiore Medical Center· Source

• Completed

  A Comparative Clinical Study to Determine the Optimal Initial Therapy for Multiple Myeloma

  NCT06151717· Mayo Clinic· Source

• Completed

  Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial

  NCT06037863· Mayo Clinic· Source

• Terminated

  Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

  NCT05580588· Phase 2· Shanghai Pharma Biotherapeutics USA Inc.· Source

• Completed

  Randomized Evaluation of Machine Learning Assisted Radiation Treatment Planning vs Standard Radiation Treatment Planning

  NCT05979883· Mayo Clinic· Source

• Terminated

  Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer

  NCT04975516· Phase 2· Mayo Clinic· Source

• Completed

  Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis

  NCT05557162· Mayo Clinic· Source

• Terminated

  Needle-Based Confocal Laser Endomicroscopy for Diagnosis of Lung Cancer in Patients With Peripheral Pulmonary Nodules

  NCT05556525· Mayo Clinic· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

• Terminated

  Oral AMXT 1501 Dicaprate in Combination With IV DFMO

  NCT05500508· Phase 1/2· Aminex Therapeutics, Inc.· Source

• Completed

  An Imaging Agent (Fluorodopa F 18) With Positron Emission Tomography/Magnetic Resonance Imaging for Assessing Treatment Response in Patients With High-Grade Soft Tissue Sarcomas

  NCT05560009· Mayo Clinic· Source

• Terminated

  E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

  NCT05388877· Phase 1· Mayo Clinic· Source

• Terminated

  Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study

  NCT05393713· Phase 1· Mayo Clinic· Source

• Completed

  A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease

  NCT05521191· Phase 1· Regulus Therapeutics Inc.· Source

• Completed

  A Drug-drug Interaction Study of Avapritinib and Midazolam

  NCT04908176· Phase 1· Blueprint Medicines Corporation· Source

• Completed

  Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)

  NCT05446870· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women

  NCT05854992· Mayo Clinic· Source

• Completed

  Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney Disease

  NCT05362786· Phase 1· LaTonya J. Hickson· Source

• Terminated

  Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

  NCT05288062· Phase 2· Mayo Clinic· Source

• Recruiting

  Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

  NCT05168163· Phase 2· Academic and Community Cancer Research United· Source

• Terminated

  Extended-Release Melatonin in Patients With Rapid Eye Movement Sleep Behavior Disorder

  NCT05307770· Mayo Clinic· Source

• Terminated

  A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene Alterations

  NCT05242822· Phase 1· Kinnate Biopharma· Source

• Completed

  Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05052801· Phase 3· Amgen· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

  NCT05186818· Phase 3· Cytokinetics· Source

• Completed

  Study to Evaluate the Safety, Tolerability, PDs, and Efficacy of CNP-104 in Subjects With Primary Biliary Cholangitis

  NCT05104853· Phase 1/2· COUR Pharmaceutical Development Company, Inc.· Source

• Completed

  An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study

  NCT05192200· Phase 2· Pfizer· Source

• Terminated

  CAM Procedure With BMAC for Shoulder OA

  NCT04826224· Phase 1· Shane A. Shapiro· Source

• Recruiting

  A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

  NCT04929223· Phase 1· Hoffmann-La Roche· Source

• Completed

  Study of Oral LOXO-338 in Patients With Advanced Blood Cancers

  NCT05024045· Phase 1· Eli Lilly and Company· Source

• Completed

  Improving Wellbeing in Ischemic Heart Disease

  NCT04974541· Mayo Clinic· Source

• Terminated

  Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

  NCT04588246· Phase 3· NRG Oncology· Source

• Terminated

  Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

  NCT04778397· Phase 3· Gilead Sciences· Source

• Terminated

  A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma

  NCT04996004· Phase 2· Pfizer· Source

• Completed

  Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT04708782· Phase 3· United Therapeutics· Source

• Completed

  Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

  NCT04493060· Phase 2· Mayo Clinic· Source

Showing 50 of 108.

Conditions

Diseases this institution publishes on or runs trials for.

• Alzheimer disease209 works · 4 trials
• Heart failure101 works · 5 trials
• Prostate cancer60 works · 28 trials
• Melanoma57 works · 29 trials
• Multiple myeloma55 works · 28 trials
• Chronic kidney disease46 works · 5 trials
• Pancreatic cancer46 works · 23 trials
• Epilepsy42 works · 7 trials
• Glioblastoma41 works · 22 trials
• Acute myeloid leukaemia37 works · 11 trials
• Glaucoma35 works · 0 trials
• Hodgkin lymphoma33 works · 1 trial
• Myocarditis30 works · 0 trials
• Frontotemporal dementia30 works · 2 trials
• Sarcoma30 works · 22 trials
• ALS (motor neurone disease)29 works · 11 trials
• Neuroendocrine tumours27 works · 12 trials
• Triple-negative breast cancer26 works · 11 trials
• Diffuse large B-cell lymphoma26 works · 5 trials
• Crohn's disease26 works · 2 trials
• Kidney cancer26 works · 11 trials
• Ulcerative colitis24 works · 0 trials
• Amyloidosis21 works · 2 trials
• Chronic lymphocytic leukaemia20 works · 6 trials
• Metastatic breast cancer19 works · 24 trials
• Myelodysplastic syndromes19 works · 13 trials
• Polycystic kidney disease16 works · 1 trial
• Lewy body dementia14 works · 2 trials
• Myeloproliferative neoplasms14 works · 6 trials
• Irritable bowel syndrome13 works · 1 trial